CytomX(CTMX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CTMX CytomX

交易中 03-17 13:01:47 EDT

5.81

-0.94

-13.93%

最高6.91	最低5.75	成交量992.03万
今开6.90	昨收6.75	日振幅17.19%
总市值9.84亿	流通市值6.57亿	总股本1.69亿
成交额6,214万	换手率8.78%	流通股本1.13亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CTMX","market":"US","secType":"STK","nameCN":"CytomX","latestPrice":5.81,"timestamp":1773766906375,"preClose":6.75,"halted":0,"volume":9920339,"delay":0,"changeRate":-0.1392592592592593,"floatShares":112999999,"shares":169435395,"eps":0.4026,"marketStatus":"交易中","change":-0.94,"latestTime":"03-17 13:01:47 EDT","open":6.9,"high":6.91,"low":5.75,"amount":62143443.899394,"amplitude":0.171852,"askPrice":5.82,"askSize":419,"bidPrice":5.8,"bidSize":344,"shortable":0,"etf":0,"ttmEps":0.4026,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1773777600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1444276800000,"exchange":"NASDAQ","adjPreClose":6.75,"preHourTrading":{"tag":"盘前","latestPrice":6.88,"preClose":6.75,"latestTime":"09:29 EDT","volume":166585,"amount":1128836.9320699999,"timestamp":1773754183360,"change":0.13,"changeRate":0.019259,"amplitude":0.056948},"postHourTrading":{"tag":"盘后","latestPrice":6.55,"preClose":6.75,"latestTime":"19:59 EDT","volume":3895332,"amount":26072723.5902,"timestamp":1773705581616,"change":-0.2,"changeRate":-0.02963,"amplitude":0.06963},"volumeRatio":0.676639,"impliedVol":0.8839,"impliedVolPercentile":0.2112},"requestUrl":"/m/hq/s/CTMX","defaultTab":"news","newsList":[{"id":"1107988125","title":"异动解读 | CytomX盘中大跌12.07%，因抗癌药物数据看好后计划募资2.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107988125","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107988125?lang=zh_cn&edition=full","pubTime":"2026-03-18 00:08","pubTimestamp":1773763723,"startTime":"0","endTime":"0","summary":"CytomX（CTMX）今日盘中大跌12.07%，引起了市场的广泛关注。消息面上，该公司在周一收盘后宣布计划进行2.5亿美元的募资，包括股票和预先筹资的认股权证，资金将用于继续开发其结直肠癌药物Varseta-M和其他管线项目。尽管该药物在早期试验中显示出前景，且股价在周一大涨44%，但募资行为通常会导致股价短期回调。此外，Guggenheim在周二早些时候将CytomX的目标价从10美元上调至15美元，预测Varseta-M在美国的调整后销售峰值为13亿美元。覆盖该股的所有9家券商均看涨该股，中位预测值为10.50美元。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CTMX"],"gpt_icon":0},{"id":"1190943112","title":"摩根大通上调CytomX评级至增持 目标价大幅提升至12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190943112","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190943112?lang=zh_cn&edition=full","pubTime":"2026-03-16 23:29","pubTimestamp":1773674950,"startTime":"0","endTime":"0","summary":"生物技术公司CytomX Therapeutics Inc（纳斯达克代码：CTMX）迎来重大利好——投资银行摩根大通最新发布研究报告，将其投资评级从\"中性\"显著上调至\"增持\"。与此同时，该机构将其目标股价从原先的7美元大幅调升至12美元，增幅超过70%，显示出对该公司未来发展前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTMX","BK4139"],"gpt_icon":0},{"id":"1115219321","title":"CytomX启动贝伐珠单抗I期研究；化疗联合Ib/II期研究拟于2026年底前展开","url":"https://stock-news.laohu8.com/highlight/detail?id=1115219321","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115219321?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:10","pubTimestamp":1773659426,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics Inc（简称CytomX）宣布已启动针对贝伐珠单抗的I期临床研究。同时，公司计划在2026年底前开展一项化疗联合疗法的Ib/II期研究。\n这两项研究旨在评估候选药物在特定患者群体中的安全性和初步疗效。贝伐珠单抗I期研究将重点关注该药物在晚期实体瘤患者中的耐受性与药代动力学特征。而拟启动的Ib/II期研究则将探索化疗联合方案在特定癌症类型中的治疗潜力。\n公司表示，上述进展符合其推进精准肿瘤疗法的战略规划。通过阶段性临床试验，CytomX期望为后续临床开发提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTMX"],"gpt_icon":0},{"id":"1190684552","title":"CytomX的Varsetatug Masetecan（EpCAM Probody® ADC）持续展现积极数据，有望成为后线结直肠癌新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1190684552","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190684552?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:09","pubTimestamp":1773659354,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics公司研发的Varsetatug Masetecan（EpCAM Probody®抗体偶联药物）最新临床数据持续呈现积极信号，这项创新疗法或将为晚期结直肠癌患者提供新的治疗选择。数据显示，该药物在经多轮治疗的患者群体中仍能保持显著抗肿瘤活性，其独特的作用机制有望突破现有后线治疗瓶颈。\n作为靶向EpCAM的精准疗法，该ADC药物通过智能探针技术有效区分病变组织与健康细胞，在提升疗效的同时显著降低毒副作用。最新临床证据进一步验证了其耐受性与临床获益率的可持续性，为后续适应症拓展奠定基础。随着结直肠癌后线治疗需求日益迫切，该疗法的开发进展备受行业关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTMX","BK4139"],"gpt_icon":0},{"id":"1161858053","title":"Cardiff Oncology宣布管理层变动 公司迈入晚期临床开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1161858053","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161858053?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:04","pubTimestamp":1769515495,"startTime":"0","endTime":"0","summary":"随着公司战略重心向晚期临床开发阶段转移，Cardiff Oncology, Inc.今日宣布对其高管团队进行重要调整。此次人事变动旨在优化组织架构，为后续关键性临床试验的推进提供更强有力的领导支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139","CTMX"],"gpt_icon":0},{"id":"1139873652","title":"异动解读 | CytomX生物科技盘前大跌6.92%，第三季度业绩远低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1139873652","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139873652?lang=zh_cn&edition=full","pubTime":"2025-11-07 17:38","pubTimestamp":1762508321,"startTime":"0","endTime":"0","summary":"生物科技公司CytomX今日盘前大跌6.92%，延续了周四夜盘交易中的跌势。这一显著跌幅主要源于公司近期发布的令人失望的第三季度财报。根据最新财报显示，CytomX第三季度营收仅为596.3万美元，远低于分析师预期的1160万美元。值得注意的是，尽管财报显示公司面临挑战，但CytomX仍保持相对稳健的现金状况。公司报告称，截至第三季度末，持有现金和投资总额为1.436亿美元，预计可以维持运营至2027年第二季度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CTMX"],"gpt_icon":0},{"id":"1156376374","title":"异动解读 | CytomX生物科技盘前大跌6.92%，第三季度业绩远低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1156376374","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156376374?lang=zh_cn&edition=full","pubTime":"2025-11-07 17:38","pubTimestamp":1762508314,"startTime":"0","endTime":"0","summary":"生物科技公司CytomX Therapeutics今日盘前股价大跌6.92%，延续了昨日夜盘下跌的趋势。这一显著跌幅主要源于公司最新发布的第三季度财报，其业绩表现远低于市场预期。根据CytomX发布的财报显示，公司第三季度营收仅为596.3万美元，远低于分析师预期的1160万美元。尽管短期业绩不佳，CytomX仍保持相对稳健的现金状况。未来CytomX能否扭转局面，提升营收水平，将成为投资者密切关注的焦点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CTMX"],"gpt_icon":0},{"id":"1133199623","title":"异动解读 | CytomX生物科技股价夜盘大跌7.16%，第三季度业绩远低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1133199623","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133199623?lang=zh_cn&edition=full","pubTime":"2025-11-07 09:03","pubTimestamp":1762477404,"startTime":"0","endTime":"0","summary":"生物科技公司CytomX在周四夜盘交易中股价大跌7.16%，引发投资者广泛关注。这一显著跌幅紧随公司发布的令人失望的第三季度财报。根据最新财报显示，CytomX第三季度营收仅为596.3万美元，远低于分析师预期的1160万美元。尽管财报显示公司面临挑战，但CytomX仍保持相对稳健的现金状况。公司报告称，截至第三季度末，持有现金和投资总额为1.436亿美元，预计可以维持运营至2027年第二季度。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CTMX"],"gpt_icon":0},{"id":"1124912125","title":"CytomX Therapeutics Inc - 2025年第三季度以1.436亿美元现金和投资收尾，预计现金流可持续至2027年第二季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1124912125","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124912125?lang=zh_cn&edition=full","pubTime":"2025-11-07 06:16","pubTimestamp":1762467369,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics Inc - 2025年第三季度以1.436亿美元现金和投资收尾，预计现金流可持续至2027年第二季度","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTMX"],"gpt_icon":0},{"id":"1115254729","title":"异动解读 | CytomX股价盘后大跌5.49%，第三季度营收大幅低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1115254729","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115254729?lang=zh_cn&edition=full","pubTime":"2025-11-07 05:35","pubTimestamp":1762464932,"startTime":"0","endTime":"0","summary":"生物技术公司CytomX在周四盘后交易中股价大跌5.49%，引起投资者关注。这一显著下跌紧随公司发布的令人失望的第三季度财报。根据最新财报显示，CytomX第三季度营收仅为596.3万美元，远低于分析师预期的1160万美元。CytomX作为一家专注于开发新型抗体疗法的生物技术公司，其收入主要来源于研发合作和里程碑付款。这次营收大幅低于预期可能表明公司在推进其管线项目或达成新的合作协议方面遇到了困难。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CTMX"],"gpt_icon":0},{"id":"1111931144","title":"CytomX Therapeutics 第三季度营收为596.3万美元，低于IBES预期的1160万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111931144","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111931144?lang=zh_cn&edition=full","pubTime":"2025-11-07 05:30","pubTimestamp":1762464651,"startTime":"0","endTime":"0","summary":"11月6日 - CytomX Therapeutics 第三季度运营支出为2173.1万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTMX","BK4139"],"gpt_icon":0},{"id":"1116679824","title":"新闻稿：CytomX Therapeutics任命Rachael Lester为首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1116679824","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116679824?lang=zh_cn&edition=full","pubTime":"2025-10-21 04:07","pubTimestamp":1760990851,"startTime":"0","endTime":"0","summary":"南旧金山，加利福尼亚州，2025年10月20日-- CytomX Therapeutics, Inc.是一家在面向条件激活生物制剂领域处于领先地位的公司，今天宣布任命Rachael Lester为高级副总裁兼首席商务官。在此职位上，Lester女士将负责公司的战略和业务发展职能。CytomX Therapeutics的总裁兼首席执行官Sean McCarthy博士说道。Lester女士之前在Bruin Biometrics和Onyx Pharmaceuticals担任企业战略、投资组合管理和商业化高级职务。CytomX目前的临床阶段管道包括CX-2051和CX-801。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","R","CTMX","BK4139","BK4022"],"gpt_icon":0},{"id":"1122849062","title":"CytomX Therapeutics第四季度GAAP每股收益$0.23，超出$(0.20)预期，销售额$38.09M超出$19.42M预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1122849062","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122849062?lang=zh_cn&edition=full","pubTime":"2025-03-07 05:40","pubTimestamp":1741297242,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics  报告季度每股收益$0.23，超过分析师共识预期的$，增长215%。与去年同期的每股收益$0.01相比增加了2200%。以上内容来自Benzinga Earnings专栏，原文如下：$CytomX$ $Therapeutics$  reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $ by 215 percent. This is a 2200 percent increase over earnings of $0.01 per share from the same period last year.  The company reported quarterly sales of $38.09 million which beat the analyst consensus estimate of $19.42 million by 96.19 percent.  This is a 43.17 percen","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CytomX Therapeutics第四季度GAAP每股收益$0.23，超出$(0.20)预期，销售额$38.09M超出$19.42M预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTMX"],"gpt_icon":0},{"id":"2510863283","title":"Cytomx Therapeutics, Inc.盘中异动 大幅下挫5.40%报0.795美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510863283","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510863283?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:37","pubTimestamp":1739198253,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时37分，Cytomx Therapeutics, Inc.股票出现异动，股价快速下跌5.40%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Ocean Biomedical, Inc.、Nls Pharmaceutics Ltd.涨幅较大，Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为987.05%、664.57%、268.03%，振幅较大的相关个股有Ocean Biomedical, Inc.、Invivyd, Inc.、Nls Pharmaceutics Ltd.，振幅分别为34.46%、29.90%、22.45%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223734abc9a6d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223734abc9a6d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CTMX","BK4139"],"gpt_icon":0},{"id":"2509049252","title":"Cytomx Therapeutics, Inc.盘中异动 股价大跌5.08%报0.890美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509049252","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509049252?lang=zh_cn&edition=full","pubTime":"2025-02-07 01:36","pubTimestamp":1738863387,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日01时36分，Cytomx Therapeutics, Inc.股票出现波动，股价急速下挫5.08%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。其相关个股中，Lipella Pharmaceuticals Inc.、Palatin Technologies, Inc.、Geovax Labs Inc C/Wts 29/09/2025涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc较为活跃，换手率分别为6297.64%、1646.64%、165.02%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Palatin Technologies, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ，振幅分别为125.58%、58.78%、53.02%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207013627961a34f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207013627961a34f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CTMX","BK4139"],"gpt_icon":0},{"id":"2509237797","title":"Cytomx Therapeutics, Inc.盘中异动 股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509237797","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509237797?lang=zh_cn&edition=full","pubTime":"2025-02-06 02:43","pubTimestamp":1738781037,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日02时43分，Cytomx Therapeutics, Inc.股票出现异动，股价快速上涨5.07%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.26%。其相关个股中，Invivyd, Inc.、Transcode Therapeutics, Inc.、Celularity Inc C/Wts 16/07/2026 涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4590.20%、2316.60%、1731.32%，振幅较大的相关个股有Oragenics Inc.、Transcode Therapeutics, Inc.、Invivyd, Inc.，振幅分别为132.24%、99.51%、63.99%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206024357abc3b239&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206024357abc3b239&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CTMX"],"gpt_icon":0},{"id":"2507967236","title":"Cytomx Therapeutics, Inc.盘中异动 大幅上涨5.90%报0.868美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507967236","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507967236?lang=zh_cn&edition=full","pubTime":"2025-01-31 03:17","pubTimestamp":1738264624,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日03时17分，Cytomx Therapeutics, Inc.股票出现波动，股价急速上涨5.90%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Immatics N V C/Wts 01/07/2025 涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1787.15%、302.63%、244.43%，振幅较大的相关个股有Cero Therapeutics Holdings, Inc.、Immatics N V C/Wts 01/07/2025 、Alterity Therapeutics Limited，振幅分别为65.98%、64.10%、61.86%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131031705a23483e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131031705a23483e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CTMX"],"gpt_icon":0},{"id":"2506893882","title":"Cytomx Therapeutics, Inc.盘中异动 急速拉升5.75%报0.918美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506893882","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506893882?lang=zh_cn&edition=full","pubTime":"2025-01-25 00:45","pubTimestamp":1737737132,"startTime":"0","endTime":"0","summary":"北京时间2025年01月25日00时45分，Cytomx Therapeutics, Inc.股票出现波动，股价快速拉升5.75%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。其相关个股中，Neuphoria Therapeutics Inc.、Evaxion Biotech As、Pmgc Holdings Inc.涨幅较大，Evaxion Biotech As、Pmgc Holdings Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为3933.45%、2145.02%、1600.40%，振幅较大的相关个股有Neuphoria Therapeutics Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Evaxion Biotech As，振幅分别为193.98%、134.08%、112.09%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125004532abb76cc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125004532abb76cc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTMX","LENZ"],"gpt_icon":0},{"id":"2503915647","title":"Cytomx Therapeutics, Inc.盘中异动 早盘股价大跌5.07%报0.815美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503915647","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503915647?lang=zh_cn&edition=full","pubTime":"2025-01-16 23:08","pubTimestamp":1737040081,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日23时08分，Cytomx Therapeutics, Inc.股票出现异动，股价快速下挫5.07%。截至发稿，该股报0.815美元/股，成交量13.2748万股，换手率0.17%，振幅4.13%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.01%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116230802986893eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116230802986893eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTMX","BK4139","LENZ"],"gpt_icon":0},{"id":"2501977691","title":"Cytomx Therapeutics, Inc.盘中异动 早盘大幅下跌5.15%报0.968美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501977691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501977691?lang=zh_cn&edition=full","pubTime":"2025-01-08 23:12","pubTimestamp":1736349121,"startTime":"0","endTime":"0","summary":"北京时间2025年01月08日23时12分，Cytomx Therapeutics, Inc.股票出现异动，股价快速下挫5.15%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Sana Biotechnology, Inc.、Silo Pharma, Inc.、Vir Biotechnology, Inc.涨幅较大，Silo Pharma, Inc.、60 Degrees Pharmaceuticals, Inc.、Nls Pharmaceutics Ltd.较为活跃，换手率分别为2452.71%、559.74%、527.80%，振幅较大的相关个股有Sana Biotechnology, Inc.、Silo Pharma, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 ，振幅分别为154.55%、139.44%、68.53%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108231201a21a5d49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108231201a21a5d49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTMX","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cytomx.com","stockEarnings":[{"period":"1week","weight":0.3419},{"period":"1month","weight":0.2688},{"period":"3month","weight":0.5882},{"period":"6month","weight":2.4974},{"period":"1year","weight":9.391},{"period":"ytd","weight":0.5845}],"compareEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0145},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.1887},{"period":"ytd","weight":-0.0189}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"CytomX Therapeutics, Inc.于2010年9月在特拉华州注册成立。该公司是一家临床阶段、专注于肿瘤学的生物制药公司，专注于开发旨在定位于肿瘤微环境的新型条件激活生物制剂。该公司专有、多功能、多模态的PROBODY技术平台旨在使肿瘤微环境内的生物治疗候选药物能够有条件地激活，同时最大限度地减少健康组织和循环中的药物活性。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.095227},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.029398},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.007855},{"month":4,"riseRate":0.5,"avgChangeRate":-0.008506},{"month":5,"riseRate":0.4,"avgChangeRate":0.194203},{"month":6,"riseRate":0.4,"avgChangeRate":-0.036107},{"month":7,"riseRate":0.3,"avgChangeRate":-0.048857},{"month":8,"riseRate":0.4,"avgChangeRate":-0.016225},{"month":9,"riseRate":0.3,"avgChangeRate":0.034688},{"month":10,"riseRate":0.3,"avgChangeRate":-0.069949},{"month":11,"riseRate":0.818182,"avgChangeRate":0.178681},{"month":12,"riseRate":0.454545,"avgChangeRate":0.003835}],"exchange":"NASDAQ","name":"CytomX","nameEN":"CytomX Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CytomX(CTMX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CytomX(CTMX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CytomX,CTMX,CytomX股票,CytomX股票老虎,CytomX股票老虎国际,CytomX行情,CytomX股票行情,CytomX股价,CytomX股市,CytomX股票价格,CytomX股票交易,CytomX股票购买,CytomX股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CytomX(CTMX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CytomX(CTMX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}